A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)

NCT01507194 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Postoperative Nausea and Vomiting

Interventions

DRUG: Ondansetron
DRUG: Vestipitant

Sponsor

Accenture